<DOC>
	<DOCNO>NCT02611713</DOCNO>
	<brief_summary>This study non-interventional post-marketing observational study ( PMOS ) participant advance Parkinson 's disease ( PD ) treat Duodopa/Duopa routine clinical setting . Effectiveness treatment collect physician participant/caregiver health outcome begin PMOS enrollment ( baseline visit ) , start Duodopa/Duopa treatment via percutaneous endoscopic gastrostomy-with jejunal extension ( PEG-J ) , regularly schedule visit closest Months 3 6 , every 6 month thereafter 36 month .</brief_summary>
	<brief_title>Observational Study Evaluating Long-Term Effectiveness Duodopa/Duopa Patients With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Eligibility Duodopa/Duopa therapy accordance approve local Duodopa/Duopa label participate country . Duodopa/Duopa na√Øve participant Decision treat Duodopa/Duopa make physician prior decision approach participant participate study Prior studyrelated procedure perform , participant , legal authorize representative ( LAR ) voluntarily sign Authorization Use/Disclosure Data ( AUDD ) /informed consent form ( ICF ) accord national regulation study explain subject opportunity question answer . Any condition include contraindication section approve local Duodopa/Duopa label participate country . Participants previous surgery PD include , limited deep brain stimulation ( DBS ) cell transplantation . Participants currently treatment continuous apomorphine infusion . In case previous treatment continuous subcutaneous apomorphine infusion , must least 4 week discontinuation treatment inclusion study . MiniMental State Examination ( MMSE ) score &lt; 24 Participation concurrent interventional clinical trial . Lack motivation insufficient language skills complete study questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>effectiveness</keyword>
	<keyword>Caregiver Burden</keyword>
	<keyword>motor non-motor symptom</keyword>
	<keyword>Duodopa/Duopa</keyword>
	<keyword>fluctuation</keyword>
	<keyword>OFF time</keyword>
	<keyword>carbidopa levodopa enteral suspension ( CLES )</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>Observational</keyword>
	<keyword>tremor</keyword>
	<keyword>levodopa-carbidopa intestinal gel ( LCIG )</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Advanced Parkinson 's Disease</keyword>
	<keyword>Long-term</keyword>
</DOC>